MFN

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

Market Access

A comparison of the US MFN and German MFG.

Patients

To remain competitive, biopharma must move beyond disjointed support services and take direct responsibility for the patient journey.

News

The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.

Market Access

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.